Ipamorelin is a growth hormone secretagogue (GHS) that mimics ghrelin, primarily studied for its ability to accelerate gastrointestinal recovery after surgery, specifically reducing postoperative ileus. Evidence suggests it can significantly shorten recovery time and hospital stays. Sermorelin, a Growth Hormone-Releasing Hormone (GHRH) analog, is also a growth hormone secretagogue. Studies in our corpus explore its potential in addressing age-related sleep disturbances, improving heart function in congestive heart failure, and reducing abdominal fat in obesity by augmenting the GH-IGF-1 axis. Both peptides aim to increase endogenous growth hormone levels, but their primary investigated applications differ based on the studies indexed here.
| Ipamorelin | Sermorelin | |
|---|---|---|
| Drug class | ghrh secretagogue, ghrelin mimetic | ghrh analog |
| Studies in corpus | 45 | 89 |
| Highest evidence tier | rct | rct |
| Evidence tier mix | other · 12 preclinical animal · 22 rct · 4 in vitro · 5 review · 1 | other · 26 rct · 15 cohort · 1 in vitro · 19 preclinical animal · 22 review · 2 |
| Studies with explicit sample size | 3 | 2 |
| Head-to-head studies in corpus | 0 — indirect comparison only | |
No direct head-to-head trials in our corpus. Indirect comparison only. Ipamorelin, as a ghrelin mimetic, has shown compelling early evidence in accelerating gastrointestinal recovery post-surgery, with studies highlighting a 35% reduction in recovery time and 1.5-day shorter hospital stays. Its pharmacology, including a robust quantitative link between systemic exposure and growth hormone-releasing effects, has been mapped in healthy humans. Sermorelin, as a GHRH analog, is being explored for a broader range of applications. These include its potential to improve age-related sleep disturbances, enhance heart function in older adults with congestive heart failure by improving LVEF and cardiac remodeling, and reduce abdominal fat in obesity. Studies also acknowledge sex differences in growth hormone response to GHRH stimulation, suggesting a need for sex-specific diagnostic criteria and tailored therapeutic strategies for Growth Hormone Deficiency. The corpus contains 47 studies on Ipamorelin and 96 on Sermorelin, with both showing evidence from RCTs.
Looking for vendor-level purity, endotoxin, and HPLC data on Ipamorelin or Sermorelin? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.